Early Parkinson Disease
Key Points
Key Points
- The treatment options for the alleviation of motor symptoms in the early stages of Parkinson disease (PD) are based on the enhancement of dopaminergic tone with levodopa, monoamine oxidase inhibitors, dopamine agonists (DAs), or a combination thereof.
- The choice of initial treatment is influenced by the potential for neuropsychiatric adverse effects associated with DAs and dyskinesia and motor fluctuations associated with levodopa.
Treatment
...atment...
...odopa vs. DAs vs. MAO-B inhibitors...
...ans should counsel patients with early PD on th...
...patients with early PD who seek treatmen...
...inicians may prescribe DAs as the in...
...ns should not prescribe DAs to patient...
...escribing levod...
...uld initially prescribe immediate-r...
...with early PD, clinicians should prescr...
...icians should routinely monitor pati...
...d counsel patients taking levodopa that...
...cians should counsel patients that in la...
...scribing DAs...
...uld inform the patient and caregiver (when pre...
...should screen patients for cogniti...
...ns should screen patients for the presence...
...cians should involve caregivers in assessments...
...inicians may screen patients for the prese...
...uld integrate patient preferences co...
...d prescribe the lowest dose of DA re...
...apering and Disconti...
...hould recommend tapering or discontinuation...
...DAs must be discontinued due to adverse e...
...ng MAO-B inhibitors...
...should counsel patients with early...
...y prescribe MAO-B inhibitors as the initial dopam...
Medications for Parkinson DiseaseHavin...